WK-X-34

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H405110

CAS#: 908859-10-9

Description: WK-X-34 is inhibitor of P-glycoprotein and Breast Cancer Resistance Protein (BCRP).

Chemical Structure

img
WK-X-34
CAS# 908859-10-9
Instruction

Theoretical Analysis

Hodoodo Cat#: H405110
Name: WK-X-34
CAS#: 908859-10-9
Chemical Formula: C35H37N3O6
Exact Mass: 595.27
Molecular Weight: 595.685
Elemental Analysis: C, 70.57; H, 6.26; N, 7.05; O, 16.12

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: WKX34; WKX-34; WKX 34; WK-X-34; WK-X 34; WK-X34.

IUPAC/Chemical Name: N-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)phenyl)-3,4-dimethoxybenzamide

InChi Key: WKEBQZAUNGERGA-UHFFFAOYSA-N

InChi Code: InChI=1S/C35H37N3O6/c1-41-30-14-11-25(20-31(30)42-2)34(39)37-29-8-6-5-7-28(29)35(40)36-27-12-9-23(10-13-27)15-17-38-18-16-24-19-32(43-3)33(44-4)21-26(24)22-38/h5-14,19-21H,15-18,22H2,1-4H3,(H,36,40)(H,37,39)

SMILES Code: O=C(NC1=CC=CC=C1C(NC2=CC=C(CCN3CC4=C(C=C(OC)C(OC)=C4)CC3)C=C2)=O)C5=CC=C(OC)C(OC)=C5

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 595.68 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jekerle V, Klinkhammer W, Scollard DA, Breitbach K, Reilly RM, Piquette-Miller M, Wiese M. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. Int J Cancer. 2006 Jul 15;119(2):414-22. PubMed PMID: 16646006.

2: Jekerle V, Klinkhammer W, Reilly RM, Piquette-Miller M, Wiese M. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. Cancer Chemother Pharmacol. 2007 Jan;59(1):61-9. Epub 2006 Apr 25. PubMed PMID: 16636798.

3: Jekerle V, Wang JH, Scollard DA, Reilly RM, Wiese M, Piquette-Miller M. 99mTc-Sestamibi, a sensitive probe for in vivo imaging of P-glycoprotein inhibition by modulators and mdr1 antisense oligodeoxynucleotides. Mol Imaging Biol. 2006 Nov-Dec;8(6):333-9. PubMed PMID: 16955376.

4: Michaelis M, Selt F, Rothweiler F, Wiese M, Cinatl J Jr. ABCG2 impairs the activity of the aurora kinase inhibitor tozasertib but not of alisertib. BMC Res Notes. 2015 Sep 28;8:484. doi: 10.1186/s13104-015-1405-4. PubMed PMID: 26415506; PubMed Central PMCID: PMC4587578.

5: Liu B, Qiu Q, Zhao T, Jiao L, Hou J, Li Y, Qian H, Huang W. Discovery of novel P-glycoprotein-mediated multidrug resistance inhibitors bearing triazole core via click chemistry. Chem Biol Drug Des. 2014 Aug;84(2):182-91. doi: 10.1111/cbdd.12301. Epub 2014 May 14. PubMed PMID: 24750961.

6: Wu Y, Pan M, Dai Y, Liu B, Cui J, Shi W, Qiu Q, Huang W, Qian H. Design, synthesis and biological evaluation of LBM-A5 derivatives as potent P-glycoprotein-mediated multidrug resistance inhibitors. Bioorg Med Chem. 2016 May 15;24(10):2287-97. doi: 10.1016/j.bmc.2016.03.065. Epub 2016 Apr 1. PubMed PMID: 27073052.